Last kr281.70 DKK
Change Today +0.10 / 0.04%
Volume 4.3M
NOVOB On Other Exchanges
As of 11:03 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

novo nordisk a/s-b (NOVOB) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/19/14 - kr283.10
52 Week Low
10/9/13 - kr179.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVO NORDISK A/S-B (NOVOB)

Related News

No related news articles were found.

novo nordisk a/s-b (NOVOB) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

40,226 Employees
Last Reported Date: 08/7/14
Founded in 1925

novo nordisk a/s-b (NOVOB) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr15.2M
President and Chief Operating Officer
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer and Executive Vice Pres...
Total Annual Compensation: kr8.1M
Chief of Staff and Executive Vice President
Total Annual Compensation: kr7.0M
Compensation as of Fiscal Year 2013.

novo nordisk a/s-b (NOVOB) Key Developments

Novo Nordisk A/S Announces its Saxenda(R) Receives Positive 14-1 Vote in Favour of Approval from FDA Advisory Committee

Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the United States Food and Drug Administration (FDA) has completed its meeting regarding the New Drug Application (NDA) for Saxenda(R), the intended brand name for liraglutide 3 mg, a once-daily human GLP-1 analogue for the treatment of obesity.

Novo Nordisk Launches Diabetes Drug Ryzodeg in Mexico

Novo Nordisk announced that Ryzodeg (insulin degludec + insulin aspart) has been launched in Mexico for the treatment of people with type 2 diabetes. Ryzodeg is a soluble insulin combination of ultra-long-acting insulin degludec and rapid-acting insulin. Mexico represents the first country to launch Ryzodeg but Novo Nordisk has plans to launch the product in additional countries across the Latin America region. Ryzodeg marketing authorisation in the Mexican market is positive news for Novo Nordisk, which has faced difficulty in obtaining approval in other markets. Ryzodeg approval is expected to be welcomed in the Mexican market since type 2 diabetes is considered one of the main causes of death in the country and patients will likely look positively on the combination formulation of the product as it could mean fewer daily injections.

Novo Nordisk Accepts Fine for Violating Disclosure Obligation in Denmark

Novo Nordisk A/S has accepted DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by the company on 10 December 2013. In December 2013, the Danish Financial Supervisory Authority reported the company to the police for violating its obligation under Section 27 (1) of the Danish Securities Trading Act to disclose inside information as soon as possible. The reporting concerned the company's receipt of a Complete Response Letter from the US Food and Drug Administration (FDA) in the evening of 8 February 2013. In the letter, the FDA stated that approvals for the insulin products Tresiba and Ryzodeg could not be granted on the basis given. Novo Nordisk published the FDA's decision in a company announcement on 10 February 2013 following an intensive investigation and evaluation of the implications and impact of the agency's decision. In the opinion of the Danish Financial Supervisory Authority and the Public Prosecutor, Novo Nordisk should have issued a company announcement already on the 8 February 2013 evening. Novo Nordisk is of the opinion that the company announcement was issued in a timely manner. The company maintains that even if the disclosure obligation could be said to apply already on the 8 February 2013 evening, the company was entitled to delay public disclosure until the implications of the decision had been adequately analyzed, which they had been on the 10 February 2013. However, for resource reasons Novo Nordisk's management has chosen to accept the fine to avoid a lengthy lawsuit. This will finally settle the case.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVOB:DC kr281.70 DKK +0.10

NOVOB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.06 USD -0.39
Amgen Inc $144.01 USD +1.99
Bristol-Myers Squibb Co $51.51 USD +0.39
Eli Lilly & Co $66.53 USD -0.06
Reckitt Benckiser Group PLC 5,360 GBp -45.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NOVOB Industry Range
Price/Earnings 26.8x
Price/Sales 8.1x
Price/Book 18.7x
Price/Cash Flow 21.3x
TEV/Sales 6.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO NORDISK A/S-B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at